How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

383,432 results for

kidney or renal or nephrology or nephritis or haemodialysis or nephron

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Comparison of peritoneal dialysis and hemodialysis as first renal replacement therapy in patients with end-stage renal disease and diabetes: a systematic review Full Text available with Trip Pro

, Polkinghorne KR, Kerr PG, Hawley CM, Agar JW, McDonald SP. Intensive hemodialysis and mortality risk in Australian and New Zealand populations. Am J Kidney Dis. 2016;67(4):617–28. 16. Wang IK, Liang WM, Lin CL, Liu YL, Chang CT, Yen TH, et al. Impact of dialysis modality on the survival of patients with end-stage renal disease and prior stroke. International urology and nephrology. 2016;48(1):139–47. 17. Waldum-Grevbo B, Leivestad T, Reisaeter AV, Os I. Impact of initial dialysis modality on mortality (...) . 23. Kim H, Kim KH, Park K, Kang SW, Yoo TH, Ahn SV, et al. A population-based approach indicates an overall higher patient mortality with peritoneal dialysis compared to hemodialysis in Korea. Kidney Int. 2014;86(5):991–1000. 24. Heaf JG, Wehberg S. Relative survival of peritoneal dialysis and haemodialysis patients: effect of cohort and mode of dialysis initiation. PLoS One. 2014;9(3):e90119. 25. Mircescu G, Stefan G, Garneata L, Mititiuc I, Siriopol D, Covic A. Outcomes of dialytic modalities

2019 Renal Replacement Therapy

2. Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation. Full Text available with Trip Pro

Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation. Regarding lupus disease activity, morbidity and survival, limited literature concluded conflicting results when comparing hemodialysis versus peritoneal dialysis as initial renal replacement therapies (RRT) prior to transplantation, in lupus nephritis end-stage renal disease (LN-ESRD) patients (...) flare, all-cause infections, all-cause cardiovascular events, and mortality as outcome measures. Relative-Risks of outcomes between the groups measured overall effects at a 95% significance level. RevMan 5.3 computer software was used for analysis.From search, 16 eligible studies reported 15,636 LN-ESRD -patients prior to renal transplantation with 4616 patients on hemodialysis, 2089 on peritoneal dialysis, 280 directly underwent kidney transplantation, 8319 were eliminated with reasons and 332

2020 BMC Nephrology

3. Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. Full Text available with Trip Pro

Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. Intradialytic hypotension (IDH) is a common complication of haemodialysis (HD), and a risk factor of cardiovascular morbidity and death. Several clinical studies suggested that reduction of dialysate temperature, such as fixed reduction of dialysate temperature or isothermal dialysate using a biofeedback system, might improve the IDH rate.This review aimed to evaluate (...) the benefits and harms of dialysate temperature reduction for IDH among patients with chronic kidney disease requiring HD, compared with standard dialysate temperature.We searched Cochrane Kidney and Transplant's Specialised Register up to 14 May 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search

2019 Cochrane

4. A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure Full Text available with Trip Pro

A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry (...) 7 British Kidney Patient Association, , UK 8 Renal Unit, King’s College Hospital, London, UK 9 Salford Royal NHS Foundation Trust, Salford, UK * Corresponding author Email: {{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}} Citation: {{author}}{{ (($index {{(metadata.AuthorsArray.length {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} {{metadata.Title}}. {{metadata.JournalShortName

2015 NIHR HTA programme

5. First Initiative Peritoneal Dialysis versus Hemodialysis for the Treatment of Renal Failure: A Review of Clinical Effectiveness and Guidelines

modality were not associated with impaired prognosis compared with those who had HD as initial dialysis modality. However, patients for whom PD was the initial dialysis modality were more likely to switch modality or to receive kidney transplantations. The literature search for this review did not find any guidelines regarding optimal first line dialysis modality or the optimal peritoneal dialysis care for the treatment of renal failure in adult patients. Tags hemodiafiltration, hemodialysis, kidney (...) , kidneys, peritoneal dialysis, renal dialysis, Haemodialysis, Renal, dialyses Files Rapid Response Summary with Critical Appraisal Published : February 8, 2016 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Full Text available with Trip Pro

2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN).Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a multidisciplinary Task Force voted independently on their level of agreeement (...) maintenance treatment with MMF or azathioprine should follow, with no or low-dose (<7.5 mg/day) glucocorticoids. The choice of agent depends on the initial regimen and plans for pregnancy. In non-responding disease, switch of induction regimens or rituximab are recommended. In pure membranous LN with nephrotic-range proteinuria or proteinuria >1 g/24 hours despite renin-angiotensin-aldosterone blockade, MMF in combination with glucocorticoids is preferred. Assessment for kidney and extra-renal disease

2020 Annals of the rheumatic diseases

7. A bundled phosphate control intervention (4Ds) for adults with end-stage kidney disease receiving haemodialysis: A cluster randomized controlled trial

the effectiveness of a bundled self-management intervention (taking control of your phosphate with the 4Ds) to improve phosphate control among adults receiving haemodialysis. Background: Hyperphosphataemia occurs in end-stage kidney disease and is managed by diet, drinks, drugs (phosphate binder medication), and dialysis (the 4Ds). Adherence to the 4Ds is challenging for patients. Design: A pragmatic cluster randomized controlled trial with repeated measures. Methods: Participants were adults receiving (...) haemodialysis with high serum phosphate (>1.6 mmol/L for at least 3 months) recruited between August 2017 -May 2018. Cluster randomization was according to haemodialysis treatment shifts. The 'teach-back' intervention was designed to improve phosphate control. Expected outcomes were reduced serum phosphate and increased knowledge of phosphate in end-stage kidney disease, self-efficacy and adherence to diet, drugs, and dialysis. Results: There were no differences between groups at baseline. Both groups had

2021 EvidenceUpdates

8. A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure

A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 (...) , Leydon G, Santer M, Klein J, Yao GL, Murtagh F, Farrington K, Caskey F, Tomson C, Loud F, Murphy E, Elias R, Greenwood R, O'Donoghue D. A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure. Health Services and Delivery Research 2015; 3(12) Authors' objectives (1) To describe the differences between renal units in the extent and nature of CKM, (2) to explore how decisions

2015 Health Technology Assessment (HTA) Database.

9. Larger nephron size, low nephron number, and nephrosclerosis on biopsy as predictors of kidney function after donating a kidney. Full Text available with Trip Pro

Larger nephron size, low nephron number, and nephrosclerosis on biopsy as predictors of kidney function after donating a kidney. It is unclear whether structural findings in the kidneys of living kidney donors predict postdonation kidney function. We studied living kidney donors who had a kidney biopsy during donation. Nephron size was measured by glomerular volume, cortex volume per glomerulus, and mean cross-sectional tubular area. Age-specific thresholds were defined for low nephron number (...) for a follow-up visit at a median 4.4 months after donation, with measured GFR <60 mL/min/1.73 m2 in 34%, urine albumin >5 mg/24 h in 13%, and hypertension in 5.3%. Larger glomerular volume and interstitial fibrosis/tubular atrophy predicted follow-up measured GFR <60 mL/min/1.73 m2 . Larger cortex volume per glomerulus and low nephron number predicted follow-up urine albumin >5 mg/24 h. Arteriosclerosis predicted hypertension. Microstructural findings predict GFR <60 mL/min/1.73 m2 , modest increases

2019 American Journal of Transplantation

10. A Validation of the 2018 Revision of International Society of Nephrology/Renal Pathology Society Classification for Lupus Nephritis: A Cohort Study from China. (Abstract)

A Validation of the 2018 Revision of International Society of Nephrology/Renal Pathology Society Classification for Lupus Nephritis: A Cohort Study from China. A revision of the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification for lupus nephritis has been published in 2018. The current study aimed to verify the utility of this system.A total of 101 lupus nephritis patients from a large Chinese cohort who underwent renal biopsy in Peking University First (...) of Health chronicity index were independent risk factors for patients' composite renal outcomes (hazard ratio [HR] 4.100 [95% CI 1.544-10.890], p = 0.005; HR 8.584 [95% CI 2.509-29.367], p = 0.001; and HR 3.218 [95% CI 1.138-9.099], p = 0.028; respectively).The 2018 revision of the ISN/RPS classification for lupus nephritis has utility for prediction of clinical renal outcomes.© 2020 S. Karger AG, Basel.

2020 American journal of nephrology

11. Risk factors and renal outcomes of low bone mineral density in patients with non-dialysis chronic kidney disease. (Abstract)

Risk factors and renal outcomes of low bone mineral density in patients with non-dialysis chronic kidney disease. Bone disorder is a common complication of chronic kidney disease (CKD). The clinical usefulness of bone mineral density (BMD) in CKD is not well known. Our study shows that low BMD is associated with physical activity and dietary Na/K intake ratio and can predict poor renal outcome in non-dialysis CKD.Despite evidence of a link between bone mineral disorders and chronic kidney (...) disease (CKD), the clinical implications of bone mineral density (BMD) in CKD are not well established. We investigated risk factors and renal outcomes of low BMD in CKD.We analyzed data from the KNOW-CKD. BMD measured by dual-energy x-ray absorptiometry was classified by T score: normal (T score ≥ - 1.0), osteopenia (- 1.0 > T score > - 2.5), and osteoporosis (T score ≤ - 2.5) of the lumbar spine, hip, or femoral neck. Logistic regression analysis to assess risk factors of low BMD (T score < - 1.0

2020 Osteoporosis International

12. Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation

Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears (...) be recalculated from mg/dL); Renal histological damage as assessed by Jablonski scale; continuous; Jablonski score. ">Data to be extracted: secondary outcome(s) Example: 1st author, year of publication, language, journal. ">Data to be extracted: other as well as a to meta-analysis of pre-clinical studies are available. Example: A meta‐analysis will be performed for all outcome measures reported in 10 or more articles. For subgroup analysis a minimum of 8 studies per subgroup is required. If meta‐analysis

2019 PROSPERO

13. The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease

for palliative care. The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 42Dialysis is the process of filtering the blood to remove any harmful waste products, extra salt and water. There are two forms of dialysis: haemodialysis and peritoneal dialysis (NHS Choices, 2013a). Haemodialysis is the removal (...) haemodialysis £157.92 The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 42Satellite haemodialysis £148.18 Home haemodialysis £138.67 Peritoneal dialysis £65.26 Likely place in therapy The NxStage System One is likely to be used as a home-based treatment option for people with stage 5 CKD who need RRT

2014 National Institute for Health and Clinical Excellence - Advice

14. Transfers to Hemodialysis Among US Patients Initiating Renal Replacement Therapy With Peritoneal Dialysis. Full Text available with Trip Pro

Transfers to Hemodialysis Among US Patients Initiating Renal Replacement Therapy With Peritoneal Dialysis. Identifying patients who are likely to transfer from peritoneal dialysis (PD) to hemodialysis (HD) before transition could improve their subsequent care. This study developed a prediction tool for transition from PD to HD.Retrospective cohort study.Adults initiating PD between January 2008 and December 2011, followed up through June 2015, for whom data were available in the US Renal Data (...) System (USRDS).Clinical characteristics at PD initiation and peritonitis claims.Transfer to HD, with the competing outcomes of death and kidney transplantation.Outcomes were ascertained from USRDS treatment history files. Subdistribution hazards (competing-risk) models were fit using clinical characteristics at PD initiation. A nomogram was developed to classify patient risk at 1, 2, 3, and 4 years. These data were used to generate quartiles of HD transfer risk; this quartile score was incorporated

2019 American Journal of Kidney Diseases

15. Blood Pressure Variability and Outcomes in End-Stage Renal Disease Patients on Dialysis: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

. × Title First Name* Last Name* Company/Institution E-Mail* Message *indicates required fields This site is protected by reCAPTCHA and the Google and apply. Kidney and Blood Pressure Research Meta-Analysis Blood Pressure Variability and Outcomes in End-Stage Renal Disease Patients on Dialysis: A Systematic Review and Meta-Analysis Li H. a · Xue J. b · Dai W. c · Liao X. a · Zhu P. a · Zhou Q. a · a a Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China b Department (...) . External Resources Shafi T, Sozio SM, Bandeen-Roche KJ, Ephraim PL, Luly JR, St Peter WL, et al.; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Predialysis systolic BP variability and outcomes in hemodialysis patients. J Am Soc Nephrol. 2014 Apr;25(4):799–809. External Resources Selvarajah V, Pasea L, Ojha S, Wilkinson IB, Tomlinson LA. Pre-dialysis systolic blood pressure-variability is independently associated with all-cause mortality in incident haemodialysis

2020 Kidney and Blood Pressure Research

16. Management of outpatient hemodialysis during the COVID-19 pandemic: recommendations from the Canadian Society of Nephrology COVID-19 rapid response team

Management of outpatient hemodialysis during the COVID-19 pandemic: recommendations from the Canadian Society of Nephrology COVID-19 rapid response team Journal canadien de la santé et de la maladie rénale https://doi.org/10.1177/2054358120938564 Canadian Journal of Kidney Health and Disease Volume 7: 1 –15 © The Author(s) 2020 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/2054358120938564 journals.sagepub.com/home/cjk Creative Commons Non Commercial CC BY-NC (...) /2054358120938564Canadian Journal of Kidney Health and DiseaseSuri et al research-article20202020 Management of Outpatient Hemodialysis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team Rita S. Suri 1,2 , John E. Antonsen 3 , Cheryl A. Banks 4 , David A. Clark 5 , Sara N. Davison 6 , Charles H. Frenette 7 , Joanne E. Kappel 8 , Jennifer M. MacRae 9 , Fabrice Mac-Way 10 , Anna Mathew 11 , Louise M. Moist 12 , Elena Qirjazi 9 , Karthik K. Tennankore 5

2020 CPG Infobase

17. Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. (Abstract)

Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. The omission of outcomes that are of relevance to patients, clinicians, and regulators across trials in autosomal dominant polycystic kidney disease (ADPKD) limits shared decision making. The Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Initiative convened an international (...) consensus workshop on October 25, 2018, to discuss the identification and implementation of a potential core outcome set for all ADPKD trials. This article summarizes the discussion from the workshops and the SONG-PKD core outcome set. Key stakeholders including 11 patients/caregivers and 47 health professionals (nephrologists, policy makers, industry, and researchers) attended the workshop. Four themes emerged: "Relevance of trajectory and impact of kidney function" included concerns about a patient's

2020 American Journal of Kidney Diseases

18. Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial. (Abstract)

Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial. 30935177 2019 07 23 2019 07 23 0004-5772 67 1 2019 Jan The Journal of the Association of Physicians of India J Assoc Physicians India Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial. 62-66 Mehta (...) 7505585 0004-5772 0 Hematinics 0 Hemoglobins 0 Recombinant Proteins 11096-26-7 Erythropoietin 15UQ94PT4P Darbepoetin alfa Anemia complications drug therapy Darbepoetin alfa pharmacology therapeutic use Erythropoietin pharmacology therapeutic use Hematinics pharmacology therapeutic use Hemoglobins Humans Kidney Failure, Chronic Recombinant Proteins Renal Dialysis Renal Insufficiency, Chronic complications drug therapy 2019 4 3 6 0 2019 4 3 6 0 2019 7 25 6 0 ppublish 30935177

2019 The Journal of the Association of Physicians of India Controlled trial quality: uncertain

19. The relation between dialysis-requiring acute kidney injury and recovery from end-stage renal disease: a national study. Full Text available with Trip Pro

The relation between dialysis-requiring acute kidney injury and recovery from end-stage renal disease: a national study. Approximately 4-6% of incident end stage renal disease (ESRD) patients in the U.S. recover enough kidney function to discontinue dialysis but there is considerable geographic variation. We undertook this study to investigate whether state-level variations in renal recovery among incident ESRD patients correlated with state-level variations in incidence of acute kidney injury (...) requiring dialysis (AKI-D).We conducted a national cross-sectional ecological study at the state-level using data from State Inpatient Databases and U.S. Renal Data System. All hospital admissions and all ESRD patients in 18 US states (AZ, AR, CA, FL, IA, KY, MA, MD, MI, NJ, NM, NY, NV, OR, RI, SC, VT, and WA) were included. Correlation between AKI-D incidence and rate of renal recovery across states was determined using Pearson's r (overall and in subgroups). We also calculated partial correlations

2019 BMC Nephrology

20. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. Full Text available with Trip Pro

Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. New medications for anaemia associated with chronic kidney disease (CKD) are desirable, owing to the limitations of erythropoiesis-stimulating agents (ESAs), the current standard of care. Molidustat is a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor that stimulates erythropoietin production, predominately in the kidney. We (...) report methodological details of three phase III trials, named MolIdustat once dailY improves renal Anaemia By Inducing erythropoietin (MIYABI), designed primarily to investigate the efficacy of molidustat therapy in adults with renal anaemia and dialysis-dependent CKD.MIYABI Haemodialysis-Correction (HD-C) is a single-arm trial (24-week treatment duration) in approximately 25 patients on haemodialysis, currently untreated with ESAs. MIYABI Peritoneal Dialysis (PD) is a single-arm trial (36 week

2019 BMJ open Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>